Article

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical Trials

2025-06-02

Abstract excerpt

Anaplastic lymphoma kinase (ALK) rearrangements are the therapeutic targets in non-small cell lung cancer (NSCLC). Ensartinib, a second-generation ALK tyrosine kinase inhibitor (TKI), was recently approved by the FDA for the treatment of ALK-positive NSCLC. In this systematic review, we identified five studies including a total of 621 participants, by searching PubMed, Scopus, and Embase through May 2025. The phas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 492f921c-c1ad-5d69-b1a9-83f29c0dbdf9
DOI: 10.1101/2025.06.02.25328724

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical TrialsDOI 10.1101/2025.06.02.25328724Read

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.Semantic proximity Read

Sugemalimab: First Approval.Semantic proximity Read

Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Semantic proximity Read

Efficacy and safety of first-line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer: a network meta- analysisSemantic proximity Read

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.Semantic proximity Read

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialSemantic proximity Read

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohortsSemantic proximity Read

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care.Semantic proximity Read

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.Semantic proximity Read

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read